JP2022028813A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2022028813A5 JP2022028813A5 JP2021186829A JP2021186829A JP2022028813A5 JP 2022028813 A5 JP2022028813 A5 JP 2022028813A5 JP 2021186829 A JP2021186829 A JP 2021186829A JP 2021186829 A JP2021186829 A JP 2021186829A JP 2022028813 A5 JP2022028813 A5 JP 2022028813A5
- Authority
- JP
- Japan
- Prior art keywords
- infusion liquid
- liquid according
- less
- infusion
- volume
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003978 infusion fluid Substances 0.000 claims 10
- ZHSKUOZOLHMKEA-UHFFFAOYSA-N 4-[5-[bis(2-chloroethyl)amino]-1-methylbenzimidazol-2-yl]butanoic acid;hydron;chloride Chemical compound Cl.ClCCN(CCCl)C1=CC=C2N(C)C(CCCC(O)=O)=NC2=C1 ZHSKUOZOLHMKEA-UHFFFAOYSA-N 0.000 claims 3
- 229960001215 bendamustine hydrochloride Drugs 0.000 claims 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 2
- 239000008121 dextrose Substances 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 239000007788 liquid Substances 0.000 claims 2
- 229910052708 sodium Inorganic materials 0.000 claims 2
- 239000011734 sodium Substances 0.000 claims 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 239000003963 antioxidant agent Substances 0.000 claims 1
- 230000003078 antioxidant effect Effects 0.000 claims 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000012530 fluid Substances 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 230000003211 malignant effect Effects 0.000 claims 1
- 239000002504 physiological saline solution Substances 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023212014A JP2024037915A (ja) | 2012-03-20 | 2023-12-15 | 低減された投与容量を必要とする患者におけるベンダムスチン応答性症状の治療方法 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261613173P | 2012-03-20 | 2012-03-20 | |
| US61/613,173 | 2012-03-20 | ||
| US201261669889P | 2012-07-10 | 2012-07-10 | |
| US61/669,889 | 2012-07-10 | ||
| US201261678715P | 2012-08-02 | 2012-08-02 | |
| US61/678,715 | 2012-08-02 | ||
| JP2020093802A JP2020143143A (ja) | 2012-03-20 | 2020-05-29 | 低減された投与容量を必要とする患者におけるベンダムスチン応答性症状の治療方法 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020093802A Division JP2020143143A (ja) | 2012-03-20 | 2020-05-29 | 低減された投与容量を必要とする患者におけるベンダムスチン応答性症状の治療方法 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023212014A Division JP2024037915A (ja) | 2012-03-20 | 2023-12-15 | 低減された投与容量を必要とする患者におけるベンダムスチン応答性症状の治療方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022028813A JP2022028813A (ja) | 2022-02-16 |
| JP2022028813A5 true JP2022028813A5 (enExample) | 2022-06-23 |
Family
ID=49212373
Family Applications (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015501814A Active JP6224064B2 (ja) | 2012-03-20 | 2013-03-15 | 低減された投与容量を必要とする患者におけるベンダムスチン応答性症状の治療方法 |
| JP2017193917A Active JP6381761B2 (ja) | 2012-03-20 | 2017-10-04 | 低減された投与容量を必要とする患者におけるベンダムスチン応答性症状の治療方法 |
| JP2018143022A Active JP6738376B2 (ja) | 2012-03-20 | 2018-07-31 | 低減された投与容量を必要とする患者におけるベンダムスチン応答性症状の治療方法 |
| JP2020093802A Pending JP2020143143A (ja) | 2012-03-20 | 2020-05-29 | 低減された投与容量を必要とする患者におけるベンダムスチン応答性症状の治療方法 |
| JP2021186829A Pending JP2022028813A (ja) | 2012-03-20 | 2021-11-17 | 低減された投与容量を必要とする患者におけるベンダムスチン応答性症状の治療方法 |
| JP2023212014A Withdrawn JP2024037915A (ja) | 2012-03-20 | 2023-12-15 | 低減された投与容量を必要とする患者におけるベンダムスチン応答性症状の治療方法 |
Family Applications Before (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015501814A Active JP6224064B2 (ja) | 2012-03-20 | 2013-03-15 | 低減された投与容量を必要とする患者におけるベンダムスチン応答性症状の治療方法 |
| JP2017193917A Active JP6381761B2 (ja) | 2012-03-20 | 2017-10-04 | 低減された投与容量を必要とする患者におけるベンダムスチン応答性症状の治療方法 |
| JP2018143022A Active JP6738376B2 (ja) | 2012-03-20 | 2018-07-31 | 低減された投与容量を必要とする患者におけるベンダムスチン応答性症状の治療方法 |
| JP2020093802A Pending JP2020143143A (ja) | 2012-03-20 | 2020-05-29 | 低減された投与容量を必要とする患者におけるベンダムスチン応答性症状の治療方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023212014A Withdrawn JP2024037915A (ja) | 2012-03-20 | 2023-12-15 | 低減された投与容量を必要とする患者におけるベンダムスチン応答性症状の治療方法 |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US9000021B2 (enExample) |
| EP (3) | EP2827863B1 (enExample) |
| JP (6) | JP6224064B2 (enExample) |
| CN (2) | CN107157988A (enExample) |
| CA (1) | CA2867343C (enExample) |
| DK (2) | DK2827863T3 (enExample) |
| ES (2) | ES2718902T3 (enExample) |
| FI (1) | FI3533447T3 (enExample) |
| HK (1) | HK1243346A1 (enExample) |
| HR (2) | HRP20230276T1 (enExample) |
| HU (2) | HUE062230T2 (enExample) |
| LT (1) | LT2827863T (enExample) |
| PL (2) | PL3533447T3 (enExample) |
| PT (2) | PT3533447T (enExample) |
| RS (2) | RS64137B1 (enExample) |
| SI (2) | SI3533447T1 (enExample) |
| WO (1) | WO2013142359A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011094565A1 (en) | 2010-01-28 | 2011-08-04 | Eagle Pharmaceuticals, Inc. | Formulations of bendamustine |
| US20230241218A1 (en) * | 2012-07-10 | 2023-08-03 | Eagle Pharmaceuticals, Inc. | Formulations of bendamustine |
| HRP20230276T1 (hr) * | 2012-03-20 | 2023-04-28 | Eagle Pharmaceuticals, Inc. | Tekući pripravci bendamustina za uporabu u postupku liječenja stanja koja reagiraju na bendamustin kod pacijenata kojima za primjenu trebaju reducirani volumeni |
| ES2972227T3 (es) | 2012-03-20 | 2024-06-11 | Eagle Pharmaceuticals Inc | Formulaciones de bendamustina |
| US10905677B2 (en) | 2016-08-31 | 2021-02-02 | Navinta, Llc | Bendamustine solution formulations |
| US11826466B2 (en) | 2016-08-31 | 2023-11-28 | Navinta, Llc | Bendamustine solution formulations |
| EP3836921B1 (en) | 2018-08-17 | 2025-10-08 | Hospira Australia Pty Ltd | Liquid bendamustine pharmaceutical compositions |
| US11730815B2 (en) * | 2018-11-26 | 2023-08-22 | Good Health, Llc | Stable liquid pharmaceutical compositions comprising bendamustine |
| JP7235288B2 (ja) * | 2019-01-07 | 2023-03-08 | コーアイセイ株式会社 | ベンダムスチンの液体製剤 |
| CN110123747A (zh) * | 2019-04-26 | 2019-08-16 | 嘉兴市爵拓科技有限公司 | 苯达莫司汀的制剂 |
| WO2021014957A1 (ja) * | 2019-07-22 | 2021-01-28 | 富士フイルム株式会社 | ベンダムスチン注射液製剤 |
| WO2021161876A1 (ja) * | 2020-02-10 | 2021-08-19 | 富士フイルム株式会社 | ベンダムスチン液剤 |
| US20240148696A1 (en) | 2022-10-25 | 2024-05-09 | Softkemo Pharma Inc. | Lyophilized bendamustine-cyclodextrin composition |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE159289C (enExample) | 1903-10-08 | 1905-03-16 | ||
| US4071620A (en) | 1977-01-10 | 1978-01-31 | American Home Products Corporation | Stabilization of oxygen sensitive dose forms |
| DD159289A1 (de) | 1981-06-01 | 1983-03-02 | Uwe Olthoff | Verfahren zur herstellung stabiler injektionsloesungen von n-lostverbindungen |
| DE3446873A1 (de) | 1984-12-21 | 1986-07-10 | Merckle Gmbh | Fluessige diclofenac-zubereitungen |
| US5223515A (en) | 1988-08-18 | 1993-06-29 | Takeda Chemical Industries, Ltd. | Injectable solution containing a pyridyl methylsulfinylbenzimidazole |
| AU706890B2 (en) | 1994-01-24 | 1999-07-01 | Procter & Gamble Company, The | Process for solubilizing difficultly soluble pharmaceutical actives |
| ES2373864T3 (es) | 1998-04-20 | 2012-02-09 | Eisai R&D Management Co., Ltd. | Composición estabilizada que contiene un compuesto de tipo bencimidazol. |
| WO2002032427A1 (en) | 2000-10-20 | 2002-04-25 | Galephar M/F | Stable oral formulation containing benzimidazole derivative |
| RU2344821C2 (ru) | 2002-07-30 | 2009-01-27 | Уайт | Парентеральные композиции, содержащие гидроксиэфиры рапамицина |
| US20060035945A1 (en) | 2003-05-30 | 2006-02-16 | Giorgio Attardo | Triheterocyclic compounds, compositions, and methods for treating cancer or viral diseases |
| SE0401842D0 (sv) * | 2004-07-12 | 2004-07-12 | Dizlin Medical Design Ab | Infusion and injection solution of levodopa |
| EP1814544A4 (en) | 2004-11-05 | 2009-12-02 | Cephalon Inc | CANCER TREATMENTS |
| US8436190B2 (en) | 2005-01-14 | 2013-05-07 | Cephalon, Inc. | Bendamustine pharmaceutical compositions |
| KR20080039954A (ko) * | 2005-08-31 | 2008-05-07 | 오노 야꾸힝 고교 가부시키가이샤 | 점적용 주사제 |
| JPWO2008020584A1 (ja) | 2006-08-14 | 2010-01-07 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 安定な凍結乾燥製剤 |
| JP5721949B2 (ja) | 2006-10-12 | 2015-05-20 | アステックス、セラピューティックス、リミテッドＡｓｔｅｘ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｉｍｉｔｅｄ | 複合薬剤 |
| US8414909B2 (en) | 2006-11-20 | 2013-04-09 | Lutonix, Inc. | Drug releasing coatings for medical devices |
| DE102007003184A1 (de) | 2007-01-22 | 2008-07-24 | Orlowski, Michael, Dr. | Verfahren zur Beladung von strukturierten Oberflächen |
| US20090082416A1 (en) | 2007-09-25 | 2009-03-26 | Protia, Llc | Deuterium-enriched bendamustine |
| AR072777A1 (es) | 2008-03-26 | 2010-09-22 | Cephalon Inc | Formas solidas de clorhidrato de bendamustina |
| CN104224703A (zh) | 2008-09-25 | 2014-12-24 | 赛福伦公司 | 苯达莫司汀的液体配制品 |
| KR20110110293A (ko) | 2009-01-15 | 2011-10-06 | 세파론, 인코포레이티드 | 벤다무스틴 유리 염기의 신규 형태 |
| AU2010217297A1 (en) | 2009-02-25 | 2011-10-20 | Supratek Pharma, Inc. | Bendamustine cyclopolysaccharide compositions |
| US20100273730A1 (en) | 2009-04-27 | 2010-10-28 | Innopharmax, Inc. | Self-emulsifying pharmaceutical compositions of hydrophilic drugs and preparation thereof |
| JP2012525387A (ja) | 2009-04-28 | 2012-10-22 | セファロン、インク． | ベンダムスチンの経口製剤 |
| CN101584668A (zh) * | 2009-06-19 | 2009-11-25 | 江苏奥赛康药业有限公司 | 盐酸苯达莫司汀冻干粉针剂 |
| WO2010148288A2 (en) | 2009-06-19 | 2010-12-23 | Lyotropic Therapeutics, Inc. | Pharmaceutical formulations with low aqueous levels of free unbound drug |
| US8389558B2 (en) | 2009-07-20 | 2013-03-05 | Supratek Pharma Inc. | Bendamustine amphiphilic anionic compositions |
| US20110015245A1 (en) | 2009-07-20 | 2011-01-20 | Valery Alakhov | Bendamustine amphiphilic cationic compositions |
| US7772274B1 (en) | 2009-10-19 | 2010-08-10 | Scidose, Llc | Docetaxel formulations with lipoic acid |
| WO2011094565A1 (en) | 2010-01-28 | 2011-08-04 | Eagle Pharmaceuticals, Inc. | Formulations of bendamustine |
| JP5951600B2 (ja) | 2010-05-21 | 2016-07-13 | インフィニティー ファーマシューティカルズ， インコーポレイテッド | キナーゼ調節のための、化合物、組成物および方法 |
| US9655898B2 (en) | 2010-07-28 | 2017-05-23 | Eagle Pharmaceuticals, Inc. | Pharmaceutical compositions containing pemetrexed having extended storage stability |
| CN107353342B (zh) | 2011-12-05 | 2021-08-10 | X 博迪生物科学公司 | PDGF受体β结合多肽 |
| US20130210878A1 (en) * | 2012-01-24 | 2013-08-15 | Innopharma, Inc. | Bendamustine compositions and methods therefore |
| CA2864118A1 (en) | 2012-02-14 | 2013-08-22 | Eagle Pharmaceuticals, Inc. | Formulations of bendamustine |
| ES2972227T3 (es) | 2012-03-20 | 2024-06-11 | Eagle Pharmaceuticals Inc | Formulaciones de bendamustina |
| HRP20230276T1 (hr) | 2012-03-20 | 2023-04-28 | Eagle Pharmaceuticals, Inc. | Tekući pripravci bendamustina za uporabu u postupku liječenja stanja koja reagiraju na bendamustin kod pacijenata kojima za primjenu trebaju reducirani volumeni |
-
2013
- 2013-03-15 HR HRP20230276TT patent/HRP20230276T1/hr unknown
- 2013-03-15 EP EP13765020.6A patent/EP2827863B1/en active Active
- 2013-03-15 HR HRP20190693TT patent/HRP20190693T1/hr unknown
- 2013-03-15 RS RS20230252A patent/RS64137B1/sr unknown
- 2013-03-15 US US13/838,267 patent/US9000021B2/en active Active
- 2013-03-15 EP EP23161418.1A patent/EP4218756A1/en not_active Withdrawn
- 2013-03-15 PL PL19151152.6T patent/PL3533447T3/pl unknown
- 2013-03-15 DK DK13765020.6T patent/DK2827863T3/en active
- 2013-03-15 CN CN201710292508.7A patent/CN107157988A/zh active Pending
- 2013-03-15 RS RS20190433A patent/RS58744B1/sr unknown
- 2013-03-15 PT PT191511526T patent/PT3533447T/pt unknown
- 2013-03-15 LT LTEP13765020.6T patent/LT2827863T/lt unknown
- 2013-03-15 EP EP19151152.6A patent/EP3533447B1/en active Active
- 2013-03-15 PT PT13765020T patent/PT2827863T/pt unknown
- 2013-03-15 WO PCT/US2013/032295 patent/WO2013142359A1/en not_active Ceased
- 2013-03-15 HU HUE19151152A patent/HUE062230T2/hu unknown
- 2013-03-15 ES ES13765020T patent/ES2718902T3/es active Active
- 2013-03-15 PL PL13765020T patent/PL2827863T3/pl unknown
- 2013-03-15 DK DK19151152.6T patent/DK3533447T3/da active
- 2013-03-15 CA CA2867343A patent/CA2867343C/en active Active
- 2013-03-15 HU HUE13765020 patent/HUE044233T2/hu unknown
- 2013-03-15 ES ES19151152T patent/ES2943668T3/es active Active
- 2013-03-15 SI SI201332039T patent/SI3533447T1/sl unknown
- 2013-03-15 SI SI201331394T patent/SI2827863T1/sl unknown
- 2013-03-15 JP JP2015501814A patent/JP6224064B2/ja active Active
- 2013-03-15 CN CN201380023660.5A patent/CN104271135B/zh not_active Expired - Fee Related
-
2014
- 2014-11-26 US US14/554,269 patent/US20150080444A1/en not_active Abandoned
-
2015
- 2015-03-15 FI FIEP19151152.6T patent/FI3533447T3/fi active
- 2015-08-06 US US14/820,291 patent/US9579384B2/en active Active
-
2017
- 2017-10-04 JP JP2017193917A patent/JP6381761B2/ja active Active
-
2018
- 2018-02-28 HK HK18102930.9A patent/HK1243346A1/zh unknown
- 2018-07-31 JP JP2018143022A patent/JP6738376B2/ja active Active
-
2020
- 2020-05-29 JP JP2020093802A patent/JP2020143143A/ja active Pending
-
2021
- 2021-11-17 JP JP2021186829A patent/JP2022028813A/ja active Pending
-
2023
- 2023-12-15 JP JP2023212014A patent/JP2024037915A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104271135B (zh) | 在要求减少施用容量的患者中治疗苯达莫司汀响应性状况的方法 | |
| JP2023541430A5 (enExample) | ||
| JP2023541432A5 (enExample) | ||
| JP2017521499A5 (enExample) | ||
| TW201801726A (zh) | 降低嗜中性白血球減少症之組合物及方法 | |
| WO2014142220A1 (ja) | 抗腫瘍剤 | |
| JP2018526460A5 (enExample) | ||
| Zic et al. | The North American experience with photopheresis | |
| JP2023541766A5 (enExample) | ||
| JP2025148449A5 (enExample) | ||
| JP2021522246A5 (enExample) | ||
| RU2023109542A (ru) | Способы лечения заболеваний, связанных с рибонуклеотидредуктазой, ингибитором рибонуклеотидредуктазы | |
| JP2016104703A (ja) | 抗腫瘍剤 | |
| RU2002103761A (ru) | Способ лечения неоперабельного рака с метастазами в лимфоузлы | |
| TW202023568A (zh) | 用於治療癌症之組合療法 | |
| US11951152B1 (en) | Microparticle compositions for controlled delivery of telmisartan and actinomycin D | |
| HK40097690A (en) | Method of treating bendamustine-responsive conditions in patients requiring reduced volumes for administration | |
| CN111658645A (zh) | R848或r848与索拉非尼联合用于治疗癌症的药物组合物和用途 | |
| JP2024544518A5 (enExample) | ||
| CN111603470A (zh) | 伊曲康唑异构体在制备治疗鳞状非小细胞肺癌药物中的应用 | |
| HK40013204A (en) | Bendamustine liquid compositions for use in method of treating bendamustine-responsive conditions in patients requiring reduced volumes for administration | |
| Wollina et al. | PEGYLATED LIPOSOMAL ENCAPSULATED DOXORUBICIN AND BRENTUXIMAB VEDOTIN IN STAGE IIB MYCOSIS FUNGOIDES–A CASE REPORT | |
| CN110604729A (zh) | 双硫仑联合葡萄籽原花青素在制备用于治疗弥漫性大b细胞淋巴瘤药物方面的应用 | |
| JP2016104704A (ja) | 抗腫瘍剤 | |
| RU2006107140A (ru) | Способ лечения гипоксии плода в родах |